Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EBITDA (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed EBITDA for 4 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 7.73% to -$2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$7.9 million, a 0.33% change, with the full-year FY2024 number at -$8.0 million, down 112.04% from a year prior.
  • EBITDA was -$2.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, down from -$1.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $4.2 million in Q3 2023 to a low of -$4.2 million in Q2 2024.
  • A 4-year average of -$1.6 million and a median of -$2.0 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 387.81% in 2023, then crashed 542.23% in 2025.
  • 60 Degrees Pharmaceuticals' EBITDA stood at -$1.7 million in 2022, then fell by 20.52% to -$2.0 million in 2023, then fell by 3.04% to -$2.1 million in 2024, then dropped by 13.29% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's EBITDA are -$2.3 million (Q3 2025), -$1.6 million (Q2 2025), and -$1.9 million (Q1 2025).